An assay for the measurement of human growth hormone in urine (u-HGH) has been developed using commercially available reagents and its analytical variables have been investigated. The procedure is sensitive to 0·50 j.LU/L urine, has an interassay precision of 6·2-7·5 (CV%) over the standard curve, and shows good parallelism and recovery. Urine samples for the assay can be collected in plain plastic bottles, stored at room temperature for up to 24 h and, after adding preservative, at -20°C before assay for three months. There was a good correlation between the responses ofHGH in serum and in urine during clonidine and insulin stimulation tests.
SUMMARY. An assay for the measurement of human growth hormone in urine (u-HGH) has been developed using commercially available reagents and its analytical variables have been investigated. The procedure is sensitive to 0·50 j.LU/L urine, has an interassay precision of 6·2-7·5 (CV%) over the standard curve, and shows good parallelism and recovery. Urine samples for the assay can be collected in plain plastic bottles, stored at room temperature for up to 24 h and, after adding preservative, at -20°C before assay for three months. There was a good correlation between the responses ofHGH in serum and in urine during clonidine and insulin stimulation tests.
Stimulation and suppression tests for detecting abnormal human growth hormone (HGH) secretion are expensive in terms ofmedical and nursing care and unpleasant for the patient. Moreover, some children show no correlation between the response to pharmacological tests and the physiological secretion as shown by 24 h or overnight HGH profiles.'? Unfortunately, the multiple samples needed for these profiles pose practical problems for both the ward and the laboratory.
The assay of HGH in urine (u-HGH) in an overnight specimen could solve these problems and although the concentration of HGH in urine is only approximately 0·1% of that in serum, assays have recently been devised which are sensitive enough to measure this. 3 . 4 These have all used monoclonal antibodies produced in-house and, as many NHS laboratories do not have the expertise and time to make these, we have tried to develop an assay using commercially available HGH reagents from Boots-Celltech. The necessary sensitivity was sought by extracting the HGH from a large volume of urine on to solid phase anti-HGH antiserum. After centrifugation and removal of excess urine, iodinated antibody can be added and the resulting sandwich of solidphase linked antibody, u-HGH and iodinated antibody can be separated from excess label with the standard sucrose separation of the Celltech method. allowing time for most of the HGH released from the pituitary to reach the urine.' Aliquots of25 ml containing BSA (l g/L) and sodium azide (1 g/L) were stored at -20°C until assayed.
temperature and in the cold room at 4°C were superimposable. The reaction took 16 h to go to completion: at 24 h the binding showed a small decline to 92% of the maximum.
INVESTIGATION OF ASSAY VARIABLES

Effects of urine osmolality and urea concentration
These were investigated using osmolalities and urea concentrations covering the range usually found in urine. Table 1 shows that increasing the osmolality of the urine decreased the recovery of HGH significantly. The effect of urea was much less marked. In view of these results, all urine samples were dialysed before assay. (Leicester, UK); cat. no. 55447 with caps 65724). For the standard curve & QC tubes 0·1 ml sample was added to 7·5 ml buffer. The zero and lowest concentration of standard were assayed in triplicate, the other standards and QC samples in duplicate. The kit standard of approx 280 mUlL was omitted.
Solid-phase linked antibody (0,1 ml) was added to each tube. The tubes were capped and the rack was placed on a turntable mixer in the cold room at 4°C for 16~24 h. This gave end over end rotation at 10 rpm.
The tubes were then centrifuged at 1400 rpm (274 g) in a bench-top centrifuge for 8 min, their caps were removed gently and supernatant urine was aspirated with the tubes still in the centrifuge buckets. One millilitre of buffered horse serum was added to each tube to resuspend and wash the beads and they were centrifuged for a further 5 min at 274g.
The supernatants were aspirated again and the tubes transferred to Celltech cardboard racks. 0·1 ml iodinated-anti-HGH was added to each tube and the racks were shaken on an orbital agitator (Boots-Celltech) for 4 h.
Excess labelled antibody was then removed with pre-wash and sucrose solutions as provided for the Boots-Celltech serum HGH assay. This step was repeated once.
The tubes were counted in a LKB Multigamma counter using a spline fit computation for the standard curve. Low results were read off a manual linear plot of the zero and bottom two standards. Figure 1 shows a typical standard curve.
Precision
The intra-assay precision profile was calculated by the method of Wood et al" though duplicate estimations with more than 20% difference were excluded. Figure 2 shows that the CV was less than 10% over a very wide range ofbetween 2 and
490/lU/L.
The inter-assay precision varied from 7·5% CV at 14·0 pg/tube (3,73 /lUlL urine) to 6·2% CVat 900 pg/tube (240 /lUlL urine).
Sensitivity
This was defined as the HGH concentration equivalent to 2 SD above zero cpm and was calculated on the precision of duplicates from 12 assays. The mean detection limit was 1·86 pgl tube, equivalent to 0·50 /lUlL urine.
Specificity
The specificity of the assay for serum HGH has already been fully investigated by the manufacturers: of five peptide hormones tested only HPL interfered. The standard curves for HPL and HGH were not parallel but at a point half-way down the latter the apparent mass HGH/mass HPL was 0·0004.
Parallelism
Urines from 10 different patients with HGH values ranging from 36 to 504 pg/tube were assayed neat and diluted serially 112, 1/4, and 1/8 with the assay buffer. Least squares regression analysis of expected on observed values gave an equation for the regression line of Expected = 1·051 Observed -7,76 (correlation coefficient r=0'993; P<O·OOI).
Recovery of standard HGH
Standard HGH was added to 10 urines from different patients before the dialysis stage. Five concentrations of standard were used, each being added to two urines and these were put into three assays. Duplicate samples of each urine without standard were dialysed and assayed at the same time. The concentration of HGH in the original urines ranged from 1·3 to 29·2 /lUlL. The mean recovery of standard HGH was 88·4% at 29·2 /lUlL, 89·3% at 17·0 /lUlL, 90·2% at 8·8 /lUlL, 96·5% at 5·0 /lUlL and 100% at 1·3 /lUlL. The overall mean recovery was 93·9% with SD of6·8. weeks at -20°C the measured HGH concentratin was still 89·3% of the original in three urines and after 12 weeks was 91·7% in a further four unnes.
CORRELATION BETWEEN SERUM AND URINARY HGH RESPONSES TO STIMULATION
Twenty children underwent a clonidine or insulin tolerance test as part of the investigation of their short stature. The 'post test' u-HGH values were plotted against the serum values obtained, taken as the area under each response curve. Figure 3 shows a highly significant (P< 0,001) correspondence between the urinary and serum HGH responses, the correlation coefficient r being 0·847.
STABILITY IN THE FREEZER
Aliquots of six urines were taken into bottles containing either 1 giL BSA, 1 giL azide, both azide and BSA, or no preservative. The aliquots were frozen at -20°C before assay and further aliquots were re-assayed after a mean period of five weeks. Table 2 shows that it was important to use BSA plus azide as preservative: with this there was no fall in measured HGH concentration after five weeks storage. A later experiment with BSA and azide as preservative showed that after 10 
Discussion
In the past, the development of an assay for u-HGH has been hindered by the lack of sufficient sensitivity;" the serum HGH values in children during the day can vary from about 0·3 mUlL to about 60 mUlL whereas we have found that the corresponding overnight urine contains only about 20 /-lUlL. Increased sensitivity for a urine growth hormone assay can now be achieved using several different approaches. Hashida et al? for example used affinity-purified anti-HGH Fab' conjugated to horseradish peroxidase with a fluorescent substrate. A second approach" is to concentrate each urine 50-fold by Iyophilisation before dialysis and radioimmunoassay, but this is extremely laborious. A third approach, which we have chosen, is to extract the HGH from a large volume of urine on to solid particles. After centrifugation, the supernatant can be removed, reducing the volume from 7·5 ml to 0·3 ml for further reaction.
'Salt-effects' on antigen-antibody binding pose another serious problem for urine immunoassay techniques. Girard and Greenwood? showed that increasing sodium chloride concentrations decreased the binding of HGH to its antibody in a radioimmunoassay and that dialysis of the urine abolished this effect. Dialysis is time-consuming; we have therefore re-investigated this effect carefully, and found that salt-effects were indeed present. Dialysis was therefore necessary to remove the effect of varying osmolality in the different samples and to bring them to a constant pH. Our results contrast with those ofErb et al", but their assay, although not requiring dialysis, involved pre-dilution of the urine sample, thus increasing the detection limit (0'5 ng/L = 1 /-lUlL) compared with our method (0'5 /lUlL). We feel that the extra sensitivity of our procedure is essential for the assay of u-HGH in HGHdeficient children.
For a potential routine assay it is important to know the stability ofthe hormone during storage.
Erb et aU used no preservative at all while Hashida et a/. IO who used azide plus BSA found that samples without preservative lost 28% of their activity in five days. We found that samples without preservative lost 73% of their measured HGH concentration after five weeks at -20 DC, whereas those with BSA plus azide were unchanged. Neither BSA nor azide alone were fully protective.
Investigation of the specificity of the assay is difficult, as prolactin and HPL, the hormones most likely to interfere, are not available for investigation in their urinary molecular forms. Boots-Celltech have already studied the effect of serum hormones in detail and only HPL crossreacted. This makes the assay unsuitable for use in pregnant women.
The molecular forms of HGH found in urine have been studied in detail by Baumann and Abramson." They found that 77% of the HGH had a molecular weight (mol wt) of 22000 with only about 10% each of the 20000 mol wt form and an unidentified acidic form. We intend to examine the immunoreactive forms recognised by our antibodies as part of our study of the use of this assay in the diagnosis and follow-up of acromegaly.
Recoveries of standard HGH (94%) were acceptable, with only 8% difference in recovery over a 22-fold change in HGH concentration.
The precision of this assay is good and the system shows the high signal-to-noise characteristics and wide standard range ofthe serum assay.
The method is easy to perform and although it takes longer than the serum assay our results suggest that just one sample may be sufficient to give a picture of a child's physiological HGH secretion. We have studied the correspondence between serum and urinary HGH values in children undergoing stimulation tests and the correlation between the two responses was highly significant. At the moment, children being investigated for short stature undergo both a sleep test and a clonidine test. These generate 12 samples for analysis and also involve the cost of a hospital admission and the medical and nursing costs of the stimulation test. Further work is now in progress to confirm that an overnight urine sample can obviate the need for most of these admissions.
We conclude that adaptation of the Boots-Celltech serum HGH kit provides a convenient and reliable way of estimating urinary growth hormone and that this method is suitable for laboratories who do not have access to 'in-house' antibody reagents for 'two-site' assays.
